Home › Companies › IOVANCE BIOTHERAPEUTICS INC. › 2023-2024

IOVANCE BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed 2024-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

13Reported items
275Asset managers
2,654Fund votes
2024-06-11Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IOVANCE BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IOVANCE BIOTHERAPEUTICS INC.

These tallies are IOVANCE BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IOVANCE BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Dr. Dukes	158,014,469	--	--	26,837,808	40,390,510	Majority: yes
Elect Director: Dr. Countouriotis	179,910,972	--	--	4,941,305	40,390,510	Majority: yes
Elect Director: Mr. Maynard	181,374,341	--	--	3,477,936	40,390,510	Majority: yes
Elect Director: Mr. Rothbaum	182,486,148	--	--	2,366,129	40,390,510	Majority: yes
Elect Director: Dr. Vogt	183,635,378	--	--	1,216,899	40,390,510	Majority: yes
Elect Director: Dr. Weiser	177,964,197	--	--	6,888,080	40,390,510	Majority: yes
Elect Director: Ms. Yarno	182,153,723	--	--	2,698,554	40,390,510	Majority: yes

Source: IOVANCE BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-11 — read the filing on EDGAR.

How asset managers voted at the IOVANCE BIOTHERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 275 asset managers that disclosed a IOVANCE BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IOVANCE BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, by non-binding advisory vote, the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Combines 7 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 268 asset managers below cast 94% of the shares they voted on this item FOR (126,471,412 for, 7,784,294 against).

FOR: 126,471,412 (94.1%)AGAINST: 7,784,294 (5.8%)ABSTAIN: 108,383 (0.1%)

Largest asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	24,923,173	0	For
State Street	12,102,452	2,044	For
T. Rowe Price	12,010,201	0	For
BlackRock	11,577,979	62,914	For
PERCEPTIVE ADVISORS LLC	8,714,455	0	For
Artisan	6,318,874	0	For
Avoro Capital Advisors LLC	4,050,316	0	For
Soleus Capital Management, L.P.	3,992,028	0	For
Charles Schwab	3,846,883	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,956,146	0	For
Fidelity	2,790,044	0	For
MPM BioImpact LLC	2,200,000	0	For
PICTET ASSET MANAGEMENT SA	2,191,484	0	For
Palo Alto Investors LP	2,116,403	0	For
Northern Trust	1,758,342	0	For
Nuveen	1,665,324	0	For
TIAA	1,643,089	0	For
UBS	0	1,523,769	Against
DE Shaw	1,451,303	0	For
Hood River Capital Management LLC	1,431,274	0	For
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	1,260,000	Against
RICE HALL JAMES & ASSOCIATES, LLC	22,454	1,194,385	Against
NEW YORK STATE COMMON RETIREMENT FUND	1,164,734	0	For
PRINCIPAL GLOBAL INVESTORS	1,037,946	0	For
Goldman Sachs	1,025,291	0	For

Showing the 25 largest of 268 asset managers. See all 268 in the interactive database.

2. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 179,910,972WITHHELD: 4,941,305

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 179,910,972 for, 4,941,305 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 64% for, 2% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,364,980 for, 0 against).

FOR 99%

FOR: 54,364,980 (98.9%)ABSTAIN: 591,227 (1.1%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,896,721	902	For
Fidelity	2,707,543	33,121	For
Artisan	2,609,946	0	For
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	397,643	261,740	For
Principal	627,597	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
SEI	205,227	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	96,595	21,685	For
Global X	109,078	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

3. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 183,635,378WITHHELD: 1,216,899

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Vogt”): 183,635,378 for, 1,216,899 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 66% for, 0.5% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,956,207 for, 0 against).

FOR 100%

FOR: 54,956,207 (100.0%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	24,534,308	For
T. Rowe Price	5,256,361	For
BlackRock	5,241,417	For
State Street	3,897,623	For
Fidelity	2,740,664	For
Artisan	2,609,946	For
Charles Schwab	1,923,319	For
TIAA	1,643,089	For
Dimensional	730,422	For
Equitable	659,383	For
Principal	627,597	For
JPMorgan	456,188	For
Goldman Sachs	413,779	For
QUANTITATIVE MASTER SERIES LLC	378,814	For
Direxion Shares ETF Trust	376,060	For
Manager Directed Portfolios	358,033	For
AIG/SunAmerica	232,996	For
Lincoln Financial	223,364	For
SEI	205,227	For
John Hancock	200,228	For
Virtus	191,941	For
ProShares	141,508	For
DRIEHAUS MUTUAL FUNDS	135,954	For
Bridge Builder Trust	118,280	For
Global X	109,078	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

4. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Iain Dukes, D. Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 158,014,469WITHHELD: 26,837,808

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dukes”): 158,014,469 for, 26,837,808 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 56% for, 10% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (48,518,794 for, 0 against).

FOR 88%12%

FOR: 48,518,794 (88.3%)ABSTAIN: 6,437,413 (11.7%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,892,098	5,525	For
Fidelity	2,707,543	33,121	For
Artisan	0	2,609,946	Abstain
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	397,643	261,740	For
Principal	545	627,052	Abstain
JPMorgan	0	456,188	Abstain
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	0	376,060	Abstain
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	0	232,996	Abstain
Lincoln Financial	208,306	15,058	For
SEI	0	205,227	Abstain
John Hancock	112,806	87,422	For
Virtus	0	191,941	Abstain
ProShares	0	141,508	Abstain
DRIEHAUS MUTUAL FUNDS	0	135,954	Abstain
Bridge Builder Trust	96,595	21,685	For
Global X	0	109,078	Abstain

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

5. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Michael Weiser M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 177,964,197WITHHELD: 6,888,080

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Weiser”): 177,964,197 for, 6,888,080 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 64% for, 2% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,364,980 for, 0 against).

FOR 99%

FOR: 54,364,980 (98.9%)ABSTAIN: 591,227 (1.1%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,896,721	902	For
Fidelity	2,707,543	33,121	For
Artisan	2,609,946	0	For
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	397,643	261,740	For
Principal	627,597	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
SEI	205,227	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	96,595	21,685	For
Global X	109,078	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

6. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Ryan Maynard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 181,374,341WITHHELD: 3,477,936

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Maynard”): 181,374,341 for, 3,477,936 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 65% for, 1% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,955,796 for, 0 against).

FOR 99.9%

FOR: 54,955,796 (100.0%)ABSTAIN: 411 (0.0%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,897,212	411	For
Fidelity	2,740,664	0	For
Artisan	2,609,946	0	For
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	659,383	0	For
Principal	627,597	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
SEI	205,227	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	118,280	0	For
Global X	109,078	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

7. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wayne P. Rothbaum

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 182,486,148WITHHELD: 2,366,129

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 182,486,148 for, 2,366,129 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 65% for, 0.9% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,955,796 for, 0 against).

FOR 99.9%

FOR: 54,955,796 (100.0%)ABSTAIN: 411 (0.0%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,897,212	411	For
Fidelity	2,740,664	0	For
Artisan	2,609,946	0	For
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	659,383	0	For
Principal	627,597	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
SEI	205,227	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	118,280	0	For
Global X	109,078	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

8. To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wendy Yarno

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 182,153,723WITHHELD: 2,698,554

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Yarno”): 182,153,723 for, 2,698,554 withheld, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 279,756,339 outstanding shares: 65% for, 1.0% withheld (66% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,955,796 for, 0 against).

FOR 99.9%

FOR: 54,955,796 (100.0%)ABSTAIN: 411 (0.0%)

Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,897,212	411	For
Fidelity	2,740,664	0	For
Artisan	2,609,946	0	For
Charles Schwab	1,923,319	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	659,383	0	For
Principal	627,597	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
SEI	205,227	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	118,280	0	For
Global X	109,078	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

9. To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.

COMPENSATION

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,956,207 for, 0 against).

FOR: 54,956,207 (100.0%)

Largest asset managers voting on “To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Compa” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	24,534,308	For
T. Rowe Price	5,256,361	For
BlackRock	5,241,417	For
State Street	3,897,623	For
Fidelity	2,740,664	For
Artisan	2,609,946	For
Charles Schwab	1,923,319	For
TIAA	1,643,089	For
Dimensional	730,422	For
Equitable	659,383	For
Principal	627,597	For
JPMorgan	456,188	For
Goldman Sachs	413,779	For
QUANTITATIVE MASTER SERIES LLC	378,814	For
Direxion Shares ETF Trust	376,060	For
Manager Directed Portfolios	358,033	For
AIG/SunAmerica	232,996	For
Lincoln Financial	223,364	For
SEI	205,227	For
John Hancock	200,228	For
Virtus	191,941	For
ProShares	141,508	For
DRIEHAUS MUTUAL FUNDS	135,954	For
Bridge Builder Trust	118,280	For
Global X	109,078	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

10. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 71 asset managers below cast 100% of the shares they voted on this item FOR (54,956,207 for, 0 against).

FOR: 54,956,207 (100.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	24,534,308	For
T. Rowe Price	5,256,361	For
BlackRock	5,241,417	For
State Street	3,897,623	For
Fidelity	2,740,664	For
Artisan	2,609,946	For
Charles Schwab	1,923,319	For
TIAA	1,643,089	For
Dimensional	730,422	For
Equitable	659,383	For
Principal	627,597	For
JPMorgan	456,188	For
Goldman Sachs	413,779	For
QUANTITATIVE MASTER SERIES LLC	378,814	For
Direxion Shares ETF Trust	376,060	For
Manager Directed Portfolios	358,033	For
AIG/SunAmerica	232,996	For
Lincoln Financial	223,364	For
SEI	205,227	For
John Hancock	200,228	For
Virtus	191,941	For
ProShares	141,508	For
DRIEHAUS MUTUAL FUNDS	135,954	For
Bridge Builder Trust	118,280	For
Global X	109,078	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

11. To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from our 2014 Equity Incentive Plan; and

COMPENSATION

99.8% fund support · no official result

FOR 99.8%

The 65 asset managers below cast 99.8% of the shares they voted on this item FOR (52,551,314 for, 74,959 against).

FOR: 52,551,314 (99.9%)AGAINST: 74,959 (0.1%)

Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's co” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	24,534,308	0	For
T. Rowe Price	5,256,361	0	For
BlackRock	5,241,417	0	For
State Street	3,897,474	149	For
Fidelity	2,740,664	0	For
Artisan	2,609,946	0	For
TIAA	1,643,089	0	For
Dimensional	730,422	0	For
Equitable	659,383	0	For
Principal	627,052	0	For
JPMorgan	456,188	0	For
Goldman Sachs	413,779	0	For
QUANTITATIVE MASTER SERIES LLC	378,814	0	For
Direxion Shares ETF Trust	376,060	0	For
Manager Directed Portfolios	358,033	0	For
AIG/SunAmerica	232,996	0	For
Lincoln Financial	223,364	0	For
John Hancock	200,228	0	For
Virtus	191,941	0	For
ProShares	141,508	0	For
DRIEHAUS MUTUAL FUNDS	135,954	0	For
Bridge Builder Trust	118,280	0	For
Northern Trust	102,522	0	For
Prudential/PGIM	100,186	0	For
Pacific Life	95,617	0	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

12. To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company s common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from the 2014 Equity Incentive Plan.

COMPENSATION

99.9% fund support · no official result

FOR 99.9%

The 9 asset managers below cast 99.9% of the shares they voted on this item FOR (2,329,467 for, 467 against).

FOR: 2,329,467 (100.0%)AGAINST: 467 (0.0%)

Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company s co” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Charles Schwab	1,923,319	0	For
SEI	205,227	0	For
Global X	109,078	0	For
CLEARWATER INVESTMENT TRUST	63,999	0	For
TARGET PORTFOLIO TRUST	23,700	0	For
Nationwide	2,166	0	For
NEW COVENANT FUNDS	1,433	0	For
Principal	545	0	For
Prudential/PGIM	0	467	Against

13. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.9% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 99.9% of the shares they voted on this item FOR (1,900,273 for, 15 against).

FOR: 1,900,273 (100.0%)AGAINST: 15 (0.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	1,900,273	0	0	0	For
MILLER HOWARD INVESTMENTS INC /NY	0	15	0	0	Against

Largest IOVANCE BIOTHERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of IOVANCE BIOTHERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 279,756,339 shares outstanding at the time of that meeting.

Top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	8.91%
2	State Street	4.33%
3	T. Rowe Price	4.29%
4	BlackRock	4.16%
5	PERCEPTIVE ADVISORS LLC	3.12%
6	Artisan	2.26%
7	Avoro Capital Advisors LLC	1.45%
8	Soleus Capital Management, L.P.	1.43%
9	Charles Schwab	1.38%
10	GEODE CAPITAL MANAGEMENT, LLC	1.06%

Reported IOVANCE BIOTHERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IOVANCE BIOTHERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
New York, NY	10.72%	DEF14A
Wayne Rothbaum	10.72%	DEF14A
BlackRock	9.28%	13F
Vanguard Group	8.60%	13F
Malvern, PA	8.15%	DEF14A
Boston, MA	5.87%	DEF14A
State Street	3.72%	13F
Goldman Sachs	2.35%	13F
Morgan Stanley	2.00%	13F
Geode Capital	1.97%	13F

Percentages above are of 279,756,339 shares outstanding, as reported by IOVANCE BIOTHERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IOVANCE BIOTHERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At IOVANCE BIOTHERAPEUTICS INC.'s shareholder meeting held 2024-06-11, in the 2023-2024 proxy season, 275 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,654 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IOVANCE BIOTHERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers; — the reporting funds cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

IOVANCE BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.